Search Results

MorphoSys AG announced that the company has entered into a delisting agreement with Novartis BidCo AG and Novartis AG following the successful closing of the acquisition of MorphoSys by Novartis in May 2024.

Coya Therapeutics, Inc. announces that MSCI has selected the Company’s shares for inclusion in its MSCI USA Micro Cap Index at the market close of May 31, 2024.

Collegium Pharmaceutical, Inc. today announced it has entered into an authorized generic agreement with Hikma Pharmaceuticals USA Inc. (“Hikma”), pursuant to which Hikma will have the exclusive right to sell the authorized generic versions of Nucynta® and Nucynta ® ER.

With new features that make it faster and easier to use, Novoxel Inc. announces the launch of Tixel 2® to the USA.

Catheter Precision, Inc., a US based medical device company focused on electrophysiology products, is honored to be sponsor a session at the upcoming Monaco USA Arrhythmia Course taking place March 21-23 in Monaco.

MorphoSys AG announces that Novartis BidCo Germany AG informed the MorphoSys AG Management Board of its intention to merge MorphoSys AG as transferring company into Novartis BidCo Germany AG.

Sciton Inc., the leading manufacturer of medical and aesthetic lasers and light source technologies, has earned for the third consecutive year, the 2024 Top Workplace USA distinction by employee survey and research firm, Energage.

Jumpcode Genomics and Takara Bio USA, Inc., a wholly owned subsidiary of Takara Bio Inc., announced the companies have settled their patent dispute and have partnered to bring together their combined foundational IP in the field of targeted depletion of undesired transcripts such as ribosomal RNAs from NGS libraries using CRISPR-based technology.

Shimadzu Medical Systems USA, a medical division of Shimadzu Precision instruments, Inc., which is a subsidiary of Shimadzu Corporation Japan, has acquired California X-ray Imaging Services, Inc. in order to further expand its Healthcare Business in North America.

Exelixis, Inc. (Nasdaq: EXEL) today announced that it has entered into a Settlement and License Agreement (Agreement) with Cipla Ltd. and Cipla USA, Inc. (collectively Cipla).